CMMB — Chemomab Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-LegalZoom, Snail, metal miners
Chemomab to start mid-stage trial of systemic sclerosis drug in 2023; shares rise
Chemomab Therapeutics Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Chemomab Therapeutics Reports Q3 Loss Of $0.035 Per Share
Brief: Chemomab Presents Data From Study Showing Cm-101 Reduced Inflammatory, Fibrogenesis-Related Biomarkers In Patients With Severe Lung Injury Derived From Covid-19
Chemomab Therapeutics Ltd expected to post a loss of 33 cents a share - Earnings Preview
Brief: Chemomab Therapeutics To Report Third Quarter 2022 Financial Results
Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Chemomab Therapeutics reports Q2 results
Chemomab Therapeutics Ltd expected to post a loss of 25 cents a share - Earnings Preview
Brief: Chemomab Awarded New U.S. Patent For Cm-101, Its First-In-Class Ccl24 Neutralizing Antibody
Brief: Chemomab Presents Data Further Supporting The Mechanism Of Action And Potential Efficacy Of CM-101 In Primary Sclerosing Cholangitis
Brief: Chemomab Therapeutics Appoints Jill M. Quigley, Jd, To Its Board Of Directors
Brief: Chemomab Therapeutics Says Data Supporting Role Of Co's Novel Therapeutic Target Ccl24 In Systemic Sclerosis Presented At Eular 2022
Chemomab Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Chemomab Therapeutics Announces First Quarter 2022 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 24 cents a share - Earnings Preview
Brief: Chemomab Reports On Two Scientific Presentations That Support The Potential Therapeutic Utility Of CM-101 In Systemic Sclerosis
U.S. RESEARCH ROUNDUP-C4 Therapeutics, Crowdstrike Holdings, Signify Health